drugset / Trial / NCT02613026

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

NCT02613026

Phase 3 Completed 104 enrolled 307 Hospital of PLA
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.

Timeline

Start
2009-07
Primary completion
2013-03
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Other
Subject Docetaxel Small molecule 100 mg/m2 Other
Subject Pirarubicin Small molecule 50 mg/m2 Intravenous
Subject Pirarubicin Small molecule 60 mg/m2 Intravenous

Indications